Patents by Inventor Osman Berk Usta

Osman Berk Usta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250113821
    Abstract: The present invention generally relates to methods and compositions to determine viability of an organ for transplantation and other medical purposes. One aspect of the invention relates to a method for assessing the viability of an organ by measuring the energy parameters to determine the energy level of the organ by determining the stored cellular energy (e.g., ATP levels), and/or energy consumption over a particular time period of viability. The energy parameters can be compared to reference energy parameters as a highly accurate and reliable prediction of viable cell yield, and organ viability. Another aspect of the invention relates methods to preserve or extend the time period of viability of an organ any combination of (i) preservation perfusion of the organ to prevent ischemic damage, (ii) chemical metabolic suppression of the organ e.g., using metabolic suppressants, (iii) metabolic suppression by physical or environmental conditions, e.g., sub-zero non-freezing storage.
    Type: Application
    Filed: September 18, 2024
    Publication date: April 10, 2025
    Inventors: Martin L. Yarmush, Mehmet Toner, Maria-Louisa Izamis, Timothy Antonie Berendsen, Osman Berk Usta, Robert Marius Bieganski, Basak Elif Uygun, Mustafa Korkut Uygun, Sinem Perk
  • Patent number: 12239126
    Abstract: The present invention generally relates to methods and compositions to determine viability of an organ for transplantation and other medical purposes. One aspect of the invention relates to a method for assessing the viability of an organ by measuring the energy parameters to determine the energy level of the organ by determining the stored cellular energy (e.g., ATP levels), and/or energy consumption over a particular time period of viability. The energy parameters can be compared to reference energy parameters as a highly accurate and reliable prediction of viable cell yield, and organ viability. Another aspect of the invention relates methods to preserve or extend the time period of viability of an organ any combination of (i) preservation perfusion of the organ to prevent ischemic damage, (ii) chemical metabolic suppression of the organ e.g., using metabolic suppressants, (iii) metabolic suppression by physical or environmental conditions, e.g., sub-zero non-freezing storage.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: March 4, 2025
    Assignee: The General Hospital Corporation
    Inventors: Martin L. Yarmush, Mehmet Toner, Maria-Louisa Izamis, Timothy Antonie Berendsen, Robert Marius Bieganski, Osman Berk Usta, Basak Elif Uygun, Mustafa Korkut Uygun, Sinem Perk
  • Publication number: 20210039057
    Abstract: This disclosure relates to methods of super-cooling of aqueous samples with or without biological samples. The methods involve, e.g., providing a container comprising the aqueous sample; applying an immiscible liquid phase of sufficient thickness to separate the aqueous sample from air; and cooling the aqueous sample to a temperature that is below 0° C.
    Type: Application
    Filed: February 1, 2019
    Publication date: February 11, 2021
    Inventors: Osman Berk Usta, Haishui Huang, Martin Yarmush
  • Publication number: 20200236924
    Abstract: The present invention generally relates to methods and compositions to determine viability of an organ for transplantation and other medical purposes. One aspect of the invention relates to a method for assessing the viability of an organ by measuring the energy parameters to determine the energy level of the organ by determining the stored cellular energy (e.g., ATP levels), and/or energy consumption over a particular time period of viability. The energy parameters can be compared to reference energy parameters as a highly accurate and reliable prediction of viable cell yield, and organ viability. Another aspect of the invention relates methods to preserve or extend the time period of viability of an organ any combination of (i) preservation perfusion of the organ to prevent ischemic damage, (ii) chemical metabolic suppression of the organ e.g., using metabolic suppressants, (iii) metabolic suppression by physical or environmental conditions, e.g., sub-zero non-freezing storage.
    Type: Application
    Filed: December 6, 2019
    Publication date: July 30, 2020
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Martin L. Yarmush, Mehmet TONER, Maria-Louisa IZAMIS, Timothy Antonie BERENDSEN, Robert Marius BIEGANSKI, Osman Berk USTA, Basak Elif UYGUN, Mustafa Korkut UYGUN, Sinem PERK
  • Publication number: 20200071563
    Abstract: A segregated polymeric material is described that includes a silicon-based hydrophobic polymer and a copolymer comprising a silicon-based hydrophobic polymer and a hydrophilic segment, wherein the copolymer has been segregated to a surface of the material by contacting the surface with an aqueous solution. The segregated polymeric material can be used to improve the wettability and decrease the protein adsorption of a surface.
    Type: Application
    Filed: March 16, 2018
    Publication date: March 5, 2020
    Inventors: Osman Berk Usta, Ayse Asatekin Alexiou, Ayse Aslihan Gokaltun
  • Patent number: 10575515
    Abstract: The present invention generally relates to methods and compositions to determine viability of an organ for transplantation and other medical purposes. One aspect of the invention relates to a method for assessing the viability of an organ by measuring the energy parameters to determine the energy level of the organ by determining the stored cellular energy (e.g., ATP levels), and/or energy consumption over a particular time period of viability. The energy parameters can be compared to reference energy parameters as a highly accurate and reliable prediction of viable cell yield, and organ viability. Another aspect of the invention relates methods to preserve or extend the time period of viability of an organ any combination of (i) preservation perfusion of the organ to prevent ischemic damage, (ii) chemical metabolic suppression of the organ e.g., using metabolic suppressants, (iii) metabolic suppression by physical or environmental conditions, e.g., sub-zero non-freezing storage.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: March 3, 2020
    Assignee: The General Hospital Corporation
    Inventors: Martin L. Yarmush, Mehmet Toner, Maria-Louisa Izamis, Timothy Antonie Berendsen, Robert Marius Bieganski, Osman Berk Usta, Basak Elif Uygun, Mustafa Korkut Uygun, Sinem Perk
  • Publication number: 20170307595
    Abstract: Methods and devices to screen test compounds, e.g., study metabolism of test compounds, e.g., a pro-drug, by one cell, e.g., a hepatocyte, and the effect of metabolism of the test compound by the first cell on a second cell, e.g., a cancer cell, are described.
    Type: Application
    Filed: October 21, 2015
    Publication date: October 26, 2017
    Inventors: Martin Yarmush, Rohit Jindal, Shyam Sundhar Bale, Osman Berk Usta
  • Publication number: 20140030231
    Abstract: The present invention generally relates to methods and compositions to determine viability of an organ for transplantation and other medical purposes. One aspect of the invention relates to a method for assessing the viability of an organ by measuring the energy parameters to determine the energy level of the organ by determining the stored cellular energy (e.g., ATP levels), and/or energy consumption over a particular time period of viability. The energy parameters can be compared to reference energy parameters as a highly accurate and reliable prediction of viable cell yield, and organ viability. Another aspect of the invention relates methods to preserve or extend the time period of viability of an organ any combination of (i) preservation perfusion of the organ to prevent ischemic damage, (ii) chemical metabolic suppression of the organ e.g., using metabolic suppressants, (iii) metabolic suppression by physical or environmental conditions, e.g., sub-zero non-freezing storage.
    Type: Application
    Filed: May 4, 2011
    Publication date: January 30, 2014
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Martin L. Yarmush, Mehmet Toner, Maria-Louisa Izamis, Timothy Antonie Berendsen, Robert Marius Bieganski, Osman Berk Usta, Basak Elif Uygun, Mustafa Korkut Uygun, Sinem Perk